Width: | 250px |
Tradename: | Betabloc, Butidrate, Recetan |
Class: | Beta blocker |
Cas Number: | 7433-10-5 |
Pubchem: | 15177 |
Chemspiderid: | 14445 |
Unii: | N2S0PKP5L5 |
Chebi: | 135008 |
Chembl: | 358930 |
Synonyms: | Butedrine; Butydrine; Hydrobutamine; Idrobutamine |
Iupac Name: | 2-(butan-2-ylamino)-1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanol |
C: | 16 |
H: | 25 |
N: | 1 |
O: | 1 |
Smiles: | CCC(C)NCC(C1=CC2=C(CCCC2)C=C1)O |
Stdinchi: | 1S/C16H25NO/c1-3-12(2)17-11-16(18)15-9-8-13-6-4-5-7-14(13)10-15/h8-10,12,16-18H,3-7,11H2,1-2H3 |
Stdinchikey: | GVNYSERWAKVROD-UHFFFAOYSA-N |
Butidrine, sold under the brand names Betabloc, Butidrate, and Recetan among others, is a beta blocker (or β-adrenergic receptor antagonist) related to pronethalol[1] and propranolol[2] that was developed in the 1960s.[3] [4] It is not cardioselective (i.e., is not selective for the β1-adrenergic receptor over the β2-adrenergic receptor).[5] It has membrane stabilizing activity but no intrinsic sympathomimetic activity (i.e., partial agonist activity).[6] Similarly to certain other beta blockers, butidrine additionally possesses local anesthetic properties.[7]